Hot Features
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases,... Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks. The company also develops Psilocybin, which is in Phase 1 clinical study for treating methamphetamine use disorder; and Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases. Revive Therapeutics Ltd. is based in Toronto, Canada. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0.03 | 0.035 | 0.03 | 176680 | 0.03232478 | CS |
| 4 | 0.005 | 20 | 0.025 | 0.04 | 0.025 | 202049 | 0.0335566 | CS |
| 12 | -0.03 | -50 | 0.06 | 0.06 | 0.025 | 316212 | 0.03868506 | CS |
| 26 | 0.015 | 100 | 0.015 | 0.08 | 0.01 | 438326 | 0.0369987 | CS |
| 52 | 0 | 0 | 0.03 | 0.08 | 0.005 | 378441 | 0.02888646 | CS |
| 156 | -0.025 | -45.4545454545 | 0.055 | 0.08 | 0.005 | 327410 | 0.02429432 | CS |
| 260 | -0.57 | -95 | 0.6 | 0.65 | 0.005 | 353801 | 0.14860615 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.